Diagnostic imaging of salivary gland cancers: REFCOR recommendations by the formal consensus method.

Diagnostic imaging Metabolic imaging Salivary gland cancer Staging

Journal

European annals of otorhinolaryngology, head and neck diseases
ISSN: 1879-730X
Titre abrégé: Eur Ann Otorhinolaryngol Head Neck Dis
Pays: France
ID NLM: 101531465

Informations de publication

Date de publication:
29 Nov 2023
Historique:
medline: 1 12 2023
pubmed: 1 12 2023
entrez: 30 11 2023
Statut: aheadofprint

Résumé

To define the indications for each imaging modality in the screening, characterization, extension and follow-up of salivary gland tumors. The French Network of Rare Head and Neck Tumors (REFCOR) formed a steering group who drafted a narrative review of the literature published on Medline and proposed recommendations. The level of adherence to the recommendations was then assessed by a rating group, according to the formal consensus method. If a swelling of a salivary gland is palpable for 3 weeks, an ultrasound scan is recommended to confirm a tumoral lesion and rule out differential diagnoses. For a salivary gland tumor, MRI is recommended with diffusion-weighted and dynamic contrast-enhanced techniques. In the case of histologically proven malignancy or a highly suspicious lesion, a CT scan of the neck and chest is recommended to assess the tumor, lymph nodes and metastases. FDG-PET is not currently recommended in routine clinical practice for initial diagnosis, assessment of extension, evaluation of response to treatment, staging of recurrence, or follow-up of salivary gland tumors. Assessing salivary tumors is based on MRI. Extension assessment is based on neck and chest CT.

Identifiants

pubmed: 38036312
pii: S1879-7296(23)00159-X
doi: 10.1016/j.anorl.2023.11.007
pii:
doi:

Types de publication

Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Auteurs

A Varoquaux (A)

Département d'Imagerie Médicale, Hôpital La Conception, AP-HM, Aix-Marseille Univ, Marseille, France.

N Fakhry (N)

Département d'ORL et Chirurgie Cervico-Faciale, Hôpital La Conception, AP-HM, Aix-Marseille Univ, Marseille, France. Electronic address: Nicolas.fakhry@ap-hm.fr.

B Baujat (B)

Département d'ORL et Chirurgie Cervico-Faciale, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France.

B Verillaud (B)

Département d'ORL et de Chirurgie Cervico-Faciale, Hôpital Lariboisière, AP-HP, Inserm U1141, Université Paris Cité, Paris, France.

F Jegoux (F)

Département d'ORL et Chirurgie Cervico-Faciale, CHU de Rennes, Rennes, France.

B Barry (B)

Département d'ORL et Chirurgie Cervico-Faciale, Hôpital Bichat, AP-HP, Paris, France.

E Chabrillac (E)

Département de Chirurgie, Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France.

S Vergez (S)

Département de Chirurgie, Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; Département de Chirurgie ORL et Cervico-Faciale, CHU de Toulouse-Larrey, Université Toulouse III Paul Sabatier, Toulouse, France.

M Terroir-Cassou-Mounat (M)

Département de Médecine Nucléaire, Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France.

Classifications MeSH